Infrastructure 2020 & Beyond: Webinar Series
Client Alert | 1 min read | 08.19.20
Rebuilding America’s aging and technologically challenged infrastructure is increasingly seen as an imperative. The need to invest in and mobilize resources for critical infrastructure projects has become an ever greater priority given the role project development can play in lifting the U.S. economy in dire times.
Congress and the Administration are actively exploring various forms of infrastructure-related stimulus and associated legislation. We are closely monitoring, and are in regular contact with key officials who are driving the efforts. We are also working with companies focused on impacting the contours of such funding avenues and enabling legislation. Drawing upon our market-leading status in government contracting, we are also assisting clients to position themselves to be on the front end of the coming wave of infrastructure projects.
There are many moving pieces looming in the infrastructure space, with crucial questions to be answered. Among them:
- What infrastructure line items are likely to appear in forthcoming legislation?
- Who will be the major players in driving legislation development, negotiations, and enactment?
- Which industry sectors stand most to gain, or lose, depending on the outcomes?
- How will the specifics of COVID-19 experience drive project development and the formulation of new law?
- What does infrastructure even mean in our digital age?
- How can and will defense sectors, and government contracting agencies, participate?
- What regulatory, court, and arbitral litigation will fall out of these legislative and development efforts, and how will savvy businesses prepare?
With all this swirling, we are pleased to offer a webinar series focused on both the immediate opportunities associated with government stimulus and the broader set of strategic issues for companies focused on not being left behind in the coming wave of infrastructure projects in this rapidly evolving landscape.
The first program in the series will be a workshop-style brainstorming session, to make sure a broad set of perspectives is explored.
Click here to register for the first webinar in the series, "Infrastructure Stimulus Panel: How to prepare for, and influence, the extent, scope and funding of US infrastructure projects," on September 10, 2020.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection

